menu
    • menu
    [{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"AMZ002","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Amzell B.V","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amzell B.V \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amzell B.V \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kynexis Therapeutics

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kynexis Reports Topline Results of KYN-5356 for Cognitive Impairment in Schizophrenia

                            Details : KYN-5356 is a small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II. It is being evaluated for the treatment of cognitive impairment associated with schizophrenia.

                            Product Name : KYN-5356

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kynexis Therapeutics

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Kynexis Therapeutics

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kynexis Initiates Phase 1 Study Of KYN-5356 for Cognitive Impairment in Schizophrenia

                            Details : KYN-5356 is a clinical-stage small molecule targeting KAT-II in the kynurenine pathway. It is being evaluated in Phase 1 for cognitive impairment associated with schizophrenia.

                            Product Name : KYN-5356

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2024

                            Lead Product(s) : KYN-5356

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amzell B.V

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Amzell B.V

                            Netherlands arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMZ002

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amzell to Begin Phase 3 Trial of AMZ002 to Treat Infantile Epileptic Disease

                            Details : The phase 3 trial will compare AMZ002 to another active treatment in a superiority study, as a placebo-controlled trial would not be ethical for this patient population.

                            Product Name : AMZ002

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            November 27, 2020

                            Lead Product(s) : AMZ002

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth